Glaukos (NYSE:GKOS) Price Target Lowered to $120.00 at Truist Financial

Glaukos (NYSE:GKOS) had its target price cut by Truist Financial from $126.00 to $120.00 in a research report report published on Monday,Benzinga reports. They currently have a buy rating on the medical instruments supplier’s stock.

A number of other equities research analysts have also recently weighed in on the company. William Blair upgraded Glaukos to a “strong-buy” rating in a research note on Thursday, July 31st. BTIG Research reiterated a “buy” rating and issued a $118.00 price objective on shares of Glaukos in a research note on Wednesday, September 10th. Wells Fargo & Company boosted their price objective on Glaukos from $86.00 to $92.00 and gave the company an “equal weight” rating in a research note on Thursday, July 31st. Zacks Research lowered Glaukos from a “strong-buy” rating to a “hold” rating in a report on Friday, August 15th. Finally, Mizuho set a $130.00 target price on Glaukos in a report on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Glaukos currently has a consensus rating of “Moderate Buy” and an average target price of $123.58.

Glaukos Price Performance

Shares of NYSE GKOS opened at $84.74 on Monday. The company has a current ratio of 5.51, a quick ratio of 4.69 and a debt-to-equity ratio of 0.09. Glaukos has a twelve month low of $77.10 and a twelve month high of $163.71. The stock has a 50 day moving average of $90.99 and a two-hundred day moving average of $94.36. The stock has a market cap of $4.86 billion, a P/E ratio of -51.36 and a beta of 0.77.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.02. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%.The company had revenue of $124.12 million during the quarter, compared to analysts’ expectations of $115.49 million. During the same quarter in the previous year, the business earned ($0.52) earnings per share. The firm’s revenue for the quarter was up 29.7% on a year-over-year basis. Glaukos has set its FY 2025 guidance at EPS. On average, research analysts forecast that Glaukos will post -1.08 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Bessemer Group Inc. grew its holdings in Glaukos by 133.9% during the first quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 158 shares during the period. Whipplewood Advisors LLC grew its holdings in Glaukos by 3,957.1% during the first quarter. Whipplewood Advisors LLC now owns 284 shares of the medical instruments supplier’s stock worth $28,000 after acquiring an additional 277 shares during the period. First Horizon Advisors Inc. grew its holdings in Glaukos by 72.9% during the first quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier’s stock worth $37,000 after acquiring an additional 159 shares during the period. Versant Capital Management Inc grew its holdings in Glaukos by 583.9% during the first quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier’s stock worth $38,000 after acquiring an additional 327 shares during the period. Finally, Park Place Capital Corp grew its holdings in Glaukos by 68.4% during the second quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier’s stock worth $41,000 after acquiring an additional 162 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.